MedTrace Logo

Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke

NCT04811651 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2024-09-25

No results posted yet for this study

Summary

This is a doble blind, placebo controlled clinical trial to assess safety and efficacy of intravenous administration of Umbilical cord-derived Mesenchymal Stem cells in patients with ischemic stroke within 6 months of onset.

Conditions

Interventions

BIOLOGICAL

Umbilical Cord-derived Mesenchymal Stem Cells

umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.

DRUG

Placebo

intravenous placebo solution with the same appearance as the treatment group.

Sponsors & Collaborators

  • General Hospital of Shenyang Military Region

    lead OTHER

Principal Investigators

  • Chen Hui-Sheng, Doctor · General Hospital of Shenyang Military Region

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2024-07-30
Completion
2024-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811651 on ClinicalTrials.gov